Vaxcyte, Inc. $PCVX Shares Acquired by Strs Ohio

Strs Ohio grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 199.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,800 shares of the company’s stock after purchasing an additional 20,500 shares during the quarter. Strs Ohio’s holdings in Vaxcyte were worth $1,790,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PCVX. T. Rowe Price Investment Management Inc. lifted its holdings in Vaxcyte by 35.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock worth $521,213,000 after buying an additional 2,981,038 shares in the last quarter. Caligan Partners LP acquired a new position in shares of Vaxcyte in the fourth quarter worth $78,660,000. Adage Capital Partners GP L.L.C. increased its position in shares of Vaxcyte by 418.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock worth $79,592,000 after acquiring an additional 1,392,000 shares during the period. Polar Capital Holdings Plc increased its position in shares of Vaxcyte by 302.6% during the fourth quarter. Polar Capital Holdings Plc now owns 1,672,783 shares of the company’s stock worth $77,182,000 after acquiring an additional 1,257,253 shares during the period. Finally, Norges Bank acquired a new stake in shares of Vaxcyte in the fourth quarter valued at $56,703,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on PCVX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Price Performance

Shares of PCVX traded up $1.10 during midday trading on Tuesday, reaching $58.06. The stock had a trading volume of 66,886 shares, compared to its average volume of 1,494,090. The company has a market cap of $8.38 billion, a price-to-earnings ratio of -8.42 and a beta of 1.22. The company’s fifty day simple moving average is $52.21 and its two-hundred day simple moving average is $53.47. Vaxcyte, Inc. has a 1-year low of $29.08 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the business posted ($1.04) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Insider Transactions at Vaxcyte

In other news, CEO Grant Pickering sold 22,461 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the sale, the chief executive officer owned 474,703 shares of the company’s stock, valued at approximately $24,921,907.50. This trade represents a 4.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 75,448 shares of company stock valued at $4,091,197. 3.30% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.